BUPRENORPHINE-NALOXONE ABUSE AMONG PARTICIPANTS IN THE NEEDLE EXCHANGE PROGRAMME : A FINNISH TIME-TREND STUDY FROM 2008 TO 2018
Fältberg, Neea (2021-06-11)
BUPRENORPHINE-NALOXONE ABUSE AMONG PARTICIPANTS IN THE NEEDLE EXCHANGE PROGRAMME : A FINNISH TIME-TREND STUDY FROM 2008 TO 2018
Fältberg, Neea
(11.06.2021)
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
suljettu
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021061838846
https://urn.fi/URN:NBN:fi-fe2021061838846
Tiivistelmä
In Finland, buprenorphine is the most common street opioid and buprenorphine-naloxone is widely used in opioid agonist treatment. Studies concerning buprenorphine-naloxone abuse and associated factors are scarce. This research concerns the prevalence and associating factors of buprenorphine-naloxone abuse compared to monobuprenorphine abuse among people who inject drugs attending a needle exchange programme in Turku, Finland.
Information on buprenorphine and buprenorphine-naloxone abuse, sociodemographic background, and drug use profile was collected anonymously using questionnaires at four time-points from 2008 to 2018. Data on buprenorphine-naloxone was available in 2008 (n=76, 68%male), 2011 (n=97, 68% male), 2014 (n=103, 57% male), and 2018 (n=97, 56% male).
During the 10-year period, both buprenorphine and buprenorphine-naloxone abuse were common: 86%/66% in 2008, 85%/81% in 2011 and 75%/81% in 2014, and 80%/73% in 2018. Of the buprenorphine-naloxone abusers, 85-100% abused also monobuprenorphine. The respective figures for monobuprenorphine abuse without buprenorphine-naloxone abuse varied from 8 to 23% during the 10-year period. Compared to monobuprenorphine abuse, buprenorphine-naloxone abuse associated with amphetamine abuse, methadone abuse, lower education level, attending opioid agonist treatment, and needle sharing.
Key conclusions are that buprenorphine-naloxone abuse among people who inject drugs is high in South-Western Finland and buprenorphine-naloxone abuse seems to relate with more disadvantaged drug use profile compared to monobuprenorphine abuse. More effective harm reduction strategies should be aimed for opioid abusers with buprenorphine-naloxone abuse.
Information on buprenorphine and buprenorphine-naloxone abuse, sociodemographic background, and drug use profile was collected anonymously using questionnaires at four time-points from 2008 to 2018. Data on buprenorphine-naloxone was available in 2008 (n=76, 68%male), 2011 (n=97, 68% male), 2014 (n=103, 57% male), and 2018 (n=97, 56% male).
During the 10-year period, both buprenorphine and buprenorphine-naloxone abuse were common: 86%/66% in 2008, 85%/81% in 2011 and 75%/81% in 2014, and 80%/73% in 2018. Of the buprenorphine-naloxone abusers, 85-100% abused also monobuprenorphine. The respective figures for monobuprenorphine abuse without buprenorphine-naloxone abuse varied from 8 to 23% during the 10-year period. Compared to monobuprenorphine abuse, buprenorphine-naloxone abuse associated with amphetamine abuse, methadone abuse, lower education level, attending opioid agonist treatment, and needle sharing.
Key conclusions are that buprenorphine-naloxone abuse among people who inject drugs is high in South-Western Finland and buprenorphine-naloxone abuse seems to relate with more disadvantaged drug use profile compared to monobuprenorphine abuse. More effective harm reduction strategies should be aimed for opioid abusers with buprenorphine-naloxone abuse.